Q-omics provides the consensus-scored IL12A profile across patient tissues and cancer cell-line models. IL12A expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, IL12A is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, IL12A RNA expression shows 16,415 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, KICH, and UVM as cancer lineages where IL12A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL12A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL12A survival associations across molecular data types. IL12A RNA expression shows survival associations in the most cancer types (18), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL12A RNA expression–survival associations across cancer types. High IL12A expression shows unfavorable associations in KIRP, KIRC, KICH and LUSC, but favorable associations in SKCM and READ. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for IL12A RNA expression.
This table summarizes IL12A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for IL12A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL12A shows lower tumor expression in KICH, HNSC, THCA, LUSC and BRCA and higher tumor expression in LIHC. The KICH box plot shows higher IL12A RNA expression in normal versus tumor tissue (log2 FC = −0.803, t-test p < 0.001).
This table shows molecular features associated with IL12A in patient tissues and cancer cell lines. In patient samples, IL12A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, IL12A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Lymphoma.
